Preview

Российский кардиологический журнал

Расширенный поиск

АНТИТРОМБОЦИТАРНАЯ ТЕРАПИЯ В ПРОФИЛАКТИКЕ НЕБЛАГОПРИЯТНЫХ СОСУДИСТЫХ СОБЫТИЙ ПОСЛЕ КОРОНАРНОЙ РЕВАСКУЛЯРИЗАЦИИ. ЕСТЬ ЛИ КОНСЕНСУС МНЕНИЙ?

https://doi.org/10.15829/1560-4071-2014-6-71-76

Полный текст:

Аннотация

В обзоре обсуждается современное состояние вопроса о роли антитромбоцитарной терапии в профилактике сердечно-сосудистых событий у пациентов с ишемической болезнью сердца и коронарной реваскуляризацией. Рассматриваются современные препараты, являющиеся важнейшим компонентом двойной антитромбоцитарной терапии после чрескожных вмешательств. Приводятся сведения об особенностях антитромбоцитарной терапии после коронарного шунтирования. Излагаются основные положения Европейских и Американских рекомендаций. Обсуждаются спорные и нерешенные вопросы антитромбоцитарной терапии. Отмечается необходимость синтеза новых лекарственных форм и дальнейших исследований для разработки эффективной профилактики неблагоприятных сердечно-сосудистых событий после коронарной реваскуляризации.


 


 

 

 

Об авторах

Ю. И. Гринштейн
ГБОУ ВПО Красноярский государственный медицинский университет им. проф. В. Ф. Войно-Ясенецкого Минздрава России, Красноярск, Россия.
Россия
д. м.н., проф., заведующий кафедрой терапии института последипломного образования


А. А. Косинова
ГБОУ ВПО Красноярский государственный медицинский университет им. проф. В. Ф. Войно-Ясенецкого Минздрава России, Красноярск, Россия.
Россия
аспирант кафедры терапии института последипломного образования


И. Ю. Гринштейн
ГБОУ ВПО Красноярский государственный медицинский университет им. проф. В. Ф. Войно-Ясенецкого Минздрава России, Красноярск, Россия.
Россия
к. м.н., докторант кафедры поликлинической терапии, семейной медицины и ЗОЖ


Список литературы

1. O'Gara PT, Kushner FG, Ascheim DD. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Ascheim J Am Coll Cardiol. 2013; 61 (4).

2. Gasevic D, Khan NA, Qian H, et al.Outcomes following percutaneous coronary intervention and coronary artery bypass grafting surgery in Chinese, South Asian and white patients with acute myocardial infarction: administrative data analysis. Trials 2012; 13: 148.

3. Vranckx P, Kalesan B, Stefanini GG, et al. Clinicalout come of patients with stable ischaemic heart disease as compared to those with acute coronary syndrome esafter per cutaneo us coronary intervention. Eurolntervention 2014. pii: 20130306-01. [Epub ahead of print].

4. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidrogel and aspririn followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-33.

5. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidrogel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during angioplasty) Study. Circulation 2005; 111: 2099-106.

6. Von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolism, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel. Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect). Trial 2005; 112: 2946-50.

7. Tantry US, Gurbel PA. Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring. Curr Pharm Des. 2013; 19 (21): 3795-815.

8. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. JACC 2010; 56 (12): 919-33.

9. Price M. New antiplatelet therapies in development. Am J Health Syst Pharm 2008; 65 (suppl 5): S11-S15.

10. Santilli F, Vazzana N, Liani R, et al. Platelet activation in obesity and metabolic syndrome. Obesity Reviews 2012; 13 (1): 27-42.

11. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180 (7): 713-8.

12. Cuisset T, Morange PE, Alessi MC. Recent advances in the pharmacogenetics of clopidogrel. Human Genetics 2012; 131 (5): 653-64.

13. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration. A systematic meta-analysis. JACC 2010; 56 (2): 134-43.

14. Holmes DR, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American college of cardiology foundation task force on clinical expert consensus documents and the American heart association. JACC 2010; 56 (4): 321-41.

15. Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON- TIMI 38 trial: a pharmacogenetic analysis. The Lancet 2010; 376 (9749): 1312-9.

16. Hulot JS, Collet JP, Cayla G, et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post- myocardial infarction patients. Circulation: Cardiovascular Interventions 2011; 4 (5): 422-8.

17. Tamhane U, Meier P, Chetcuti S, et al. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. EuroIntervention 2009; 5 (3): 384-93.

18. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007 Jan; 153 (1): 66.e9-16.

19. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20): 2001-15.

20. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007 Jan;153 (1): 66.e9-16.

21. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circ. 2009; 119 (19): 2553-60.

22. Bonello L, Pansieri M, Mancini J, et al. High on-treatment platelet reactivity after prasugrel

23. loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. JACC 2011; 58 (5): 467-73.

24. Williams ET, Jones KO, Ponsler GD, et al. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metabolism and Disposition 2008; 36 (7): 1227-32.

25. Neubauer H, Kaiser A, Busse B, et al. Identification, evaluation and treatment of prasugrel low-response after coronary stent implantation — a preliminary study. Thrombosis Research 2010; 126 (5): e389-e391.

26. Husted S, Emanuelsson H, Heptinstall S, et al. Parmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonoist AZD 6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidrogel with aspirin. Eur Heart J 2006; 27: 1038-47.

27. Cannon CP, Hudsted S, Harrington A, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidrogel, in patients with non-ST segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. JACO 2007; 50: 1844-51.

28. Wallentin L, Becker RC, Budaj A, et al. for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl Med J 2009; 361: 1045-57.

29. Angiolillo DJ, Bhatt DL, Gurbel PA, et al. Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol 2009; 103: 40A-51A.

30. Bhatt DL, Lincoff AM, Gibson CM, et al. for the CHAMPION PLATFOR MI nvestigators. Intravenous platelet blockade with cangrelor during PCI. N Eng J Med 2009; 361: 2330-41.

31. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361: 2318-29.

32. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-st-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2012; 126 (7): 875-910.

33. Rossini R, Capodanno D, Lettieri C, et al. Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. Am J Cardiol 2011; 107 (2): 186-94.

34. Angiolillo DJ, Firstenberg MS, Price MJ, et al. BRIDGE Investigators. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012; 307 (3): 265-74.

35. Labinaz M, Ho C, Banerjee S, et al. Meta-analysis of clinical efficacy and bleeding risk with intravenous glycoprotein IIb/IIIa antagonists for percutaneous coronary intervention. Can J Cardiol 2007; 23: 963-70.

36. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569-619.

37. Hamm CW, Bassand JP, Agewall S, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) European Heart Journal 2011; 32 (23): 2999-3054.

38. Montalescot G, Sechtem U, Achenbach S. 2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease cf the European Society of Cardiology Eur Heart J 2013; 34:2949-3003.

39. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCH/AHA guideline for coronary artery bypass graft surgery: Executive summary: A report of the american college of cardiology foundation/american heart association task force on practice guidelines. Circulation 2011; 124:2610-42.

40. Vandvik PO, Lincoff AM, Gore JM, et al. American College of Chest Physicians. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2): e637S-68S.

41. Kulik А, Le May MR, Voisine P, et al. Aspirin Plus Clopidogrel Versus Aspirin Alone After Coronary Artery Bypass Grafting The Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) Trial Circulation. 2010; 122: 2680-7.


Для цитирования:


Гринштейн Ю.И., Косинова А.А., Гринштейн И.Ю. АНТИТРОМБОЦИТАРНАЯ ТЕРАПИЯ В ПРОФИЛАКТИКЕ НЕБЛАГОПРИЯТНЫХ СОСУДИСТЫХ СОБЫТИЙ ПОСЛЕ КОРОНАРНОЙ РЕВАСКУЛЯРИЗАЦИИ. ЕСТЬ ЛИ КОНСЕНСУС МНЕНИЙ? Российский кардиологический журнал. 2014;(6):71-76. https://doi.org/10.15829/1560-4071-2014-6-71-76

For citation:


Grinschtein Yu.I., Kosinova A.A., Grinschtein I.Yu. ANTIPLATELET THERAPY IN PROPHILAXY OF NEGATIVE CARDIOVASCULAR EVENTS AFTER CORONARY REVASCULARIZATION. IS THERE A CONSENSUS? Russian Journal of Cardiology. 2014;(6):71-76. (In Russ.) https://doi.org/10.15829/1560-4071-2014-6-71-76

Просмотров: 253


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)